Complete Depletion of Daratumumab Interference in Serum Samples from Plasma Cell Myeloma Patients Improves the Detection of Endogenous M-Proteins in a Preliminary Study

Complete Depletion of Daratumumab Interference in Serum Samples from Plasma Cell Myeloma Patients Improves the Detection of Endogenous M-Proteins in a Preliminary Study

Background: Therapeutic humanized IgG1 kappa monoclonal antibody (t-mAb), daratumumab (DARA) is a Food and Drug Administration approved drug for the treatment of relapsed/refractory plasma cell myeloma (PCM). DARA appears on serum protein electrophoresis (SPEP) and on serum immunofixation (sIFE) as...

Full description

Bibliographic Details
Main Authors: Hana Vakili, Sharon Koorse Germans, Xiuhua Dong, Ankit Kansagra, Hetalkumari Patel, Alagarraju Muthukumar, Ibrahim A. Hashim
Format: Article
Language:English
Published: MDPI AG 2020-04-01
Series:Diagnostics
Subjects:
plasma cell myeloma
daratumumab
CD38
serum protein electrophoresis
immunofixation
Online Access:https://www.mdpi.com/2075-4418/10/4/219

Internet

https://www.mdpi.com/2075-4418/10/4/219

Similar Items